While most medications are safe and effective, unfortunately many are also expensive. Biosimilars, new versions of a drug that are similar to the original in all significant respects, offer a potentially less expensive alternative to original biologic drugs. Professor Tore K. Kvien of the University of Oslo, Norway, and his colleagues have shown that a biosimilar, CT-P13, is clinically equal to the drug infliximab when switched from the parent to the biosimilar equivalent. This means that patients can switch to the biosimilar drug for non-medical reasons, without compromising safety, efficacy, or immunogenicity.

READ MORE